Compare DCO & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCO | SLN |
|---|---|---|
| Founded | 1849 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 678.0M |
| IPO Year | 1995 | 2010 |
| Metric | DCO | SLN |
|---|---|---|
| Price | $171.94 | $12.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $153.60 | $42.60 |
| AVG Volume (30 Days) | 154.8K | ★ 1.0M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.95 | N/A |
| Revenue | ★ $824,730,000.00 | $559,000.00 |
| Revenue This Year | $7.40 | N/A |
| Revenue Next Year | $8.59 | N/A |
| P/E Ratio | $85.32 | ★ N/A |
| Revenue Growth | ★ 4.85 | N/A |
| 52 Week Low | $84.76 | $4.19 |
| 52 Week High | $210.39 | $17.58 |
| Indicator | DCO | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 37.35 | 50.34 |
| Support Level | $161.87 | $13.01 |
| Resistance Level | $168.74 | $15.28 |
| Average True Range (ATR) | 6.13 | 0.69 |
| MACD | -2.29 | -0.17 |
| Stochastic Oscillator | 18.94 | 13.39 |
Ducommun Inc provides engineering & manufacturing services for high-performance products & high-cost-of failure applications used in the aerospace and defense, industrial, medical & other industries. The company's reportable segments are Structural Systems & Electronic Systems. Structural Systems designs, engineers, and manufactures various sizes of complex contoured aerostructure components and assemblies, and supplies composite and metal-bonded structures and assemblies. Electronic Systems designs, engineers and manufactures high-reliability electronic and electromechanical products used in technology-driven markets, including A&D and Industrial end-use markets. It generates a maximum of its revenue from the Electronic Systems.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.